Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019
| dc.creator | Zhu, Zhe | |
| dc.creator | Cai, Ting | |
| dc.creator | Fan, Lingyan | |
| dc.creator | Lou, Kehong | |
| dc.creator | Hua, Xin | |
| dc.creator | Huang, Zuoan | |
| dc.creator | Gao, Guosheng | |
| dc.date.accessioned | 2020-05-29T13:17:15Z | |
| dc.date.available | 2020-05-29T13:17:15Z | |
| dc.date.issued | 2020-06 | |
| dc.description.abstract | Objective To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). Methods 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value. Results Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease. Conclusion Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases. | pt_BR |
| dc.identifier.citation | ZHU, Z. et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. International Journal of Infectious Diseases, [S.l.], v. 95, p. 332-339, June 2020. | pt_BR |
| dc.identifier.uri | https://repositorio.ufla.br/handle/1/41274 | |
| dc.identifier.uri | http://www.sciencedirect.com/science/article/pii/S1201971220302575 | pt_BR |
| dc.language | en_US | pt_BR |
| dc.publisher | Elsevier | pt_BR |
| dc.rights | restrictAccess | pt_BR |
| dc.source | International Journal of Infectious Diseases | pt_BR |
| dc.subject | COVID-19 | pt_BR |
| dc.subject | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | pt_BR |
| dc.subject | Immune-inflammatory parameters | pt_BR |
| dc.subject | Cytokine storm | pt_BR |
| dc.subject | Interleukin 6 (IL-6) | pt_BR |
| dc.title | Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 | pt_BR |
| dc.type | Artigo | pt_BR |
Arquivos
Licença do pacote
1 - 1 de 1
Carregando...
- Nome:
- license.txt
- Tamanho:
- 953 B
- Formato:
- Item-specific license agreed upon to submission
- Descrição:
